It’s not only money that is lost, but the potential value of the drugs themselves. If potential toxicity issues could be identified early in the development cycle, variants could potentially be engineered, preserving the drug’s benefits while removing the threats. Shelved drug candidates could be rescued, and more successful drugs could be made available; especially important today because the number of drugs approved by the FDA over the past decade has dropped by over 50%, in spite of massive increases in the amount of money spent on R&D by drug companies. The total cost of developing a successful drug can now reach several billion dollars.
VistaGen, through the use of advanced stem cell technology, has found ways to create functioning heart cells that can act as a basis for a new approach to testing, offering more accurate tests that can be performed early in the development process. The result is a good sense of toxicity challenges at a time when changes can still be economically made, saving drug producers substantial time and money. VistaGen’s goal is to leverage their stem cell technology to create proprietary drug rescue variants that are as effective as the original candidates, but without the toxicity.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
